Nanoviricides Reported That The Phase 1a/1b Human Clinical Trial Of NV-CoV-2, The Company's Broad-spectrum Antiviral Drug, Is Progressing Successfully
Nanoviricides Reported That The Phase 1a/1b Human Clinical Trial Of NV-CoV-2, The Company's Broad-spectrum Antiviral Drug, Is Progressing Successfully
Nanoviricides報告稱，該公司的廣譜抗病毒藥物nv-CoV-2的1a/1b期人體臨床試驗正在順利進行
- The Company reports that its Indian collaborator and drug sponsor, Karveer Meditech Pvt. Ltd., India, has communicated that approximately 26 out of the target of 36 healthy volunteers in the various cohorts in the Phase 1a Single-Ascending-Dose ("SAD") have already completed the study. Additionally, 17 out of the target of 36 healthy volunteers in the various cohorts in the Phase 1b Multiple-Ascending-Dose ("MAD") part of the clinical trial have already completed the study.
- No adverse events or serious adverse events were found in the SAD or MAD studies to date, in either the NV-CoV-2 Oral Syrup or the NV-CoV-2 Oral Gummies administration cohorts.
- 該公司報告說，其印度合作者和藥物贊助商印度Karveer Meditech Pvt. Ltd.已表示，在1a期單劑量遞增劑量（“SAD”）不同羣體的36名健康志願者中，約有26人已經完成了這項研究。此外，在臨床試驗的1b期多劑量遞增劑量（“MAD”）部分的36名健康志願者中，有17名已經完成了這項研究。
- 迄今爲止，無論是在NV-CoV-2口服糖漿還是NV-CoV-2口服軟糖給藥隊列中，SAD或MAD研究均未發現不良事件或嚴重不良事件。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。